Search

Your search keyword '"van Linde, Myra E"' showing total 129 results
Start Over Author "van Linde, Myra E"
129 results on '"van Linde, Myra E"'

4. Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study

Author

van Opijnen, Mark P., Broekman, Marike L. D., de Vos, Filip Y. F., Cuppen, Edwin, van der Hoeven, Jacobus J. M., van Linde, Myra E., Compter, Annette, Beerepoot, Laurens V., van den Bent, Martin J., Vos, Maaike J., Fiebrich, Helle-Brit, Koekkoek, Johan A. F., Hoeben, Ann, Kho, Kuan H., Driessen, Chantal M. L., Jeltema, Hanne-Rinck, Robe, Pierre A. J. T., and Maas, Sybren L. N.

Published
2022
Full Text
View/download PDF

5. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Author

Wen, Patrick Y, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Wick, Antje, de Vos, Filip Y F L, von Bubnoff, Nikolas, van Linde, Myra E, Lai, Albert, Prager, Gerald W, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose A, Kim, Tae Min, Mason, Warren P, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel C, Gazzah, Anas, Pouessel, Damien, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Ilankumaran, Palanichamy, Gasal, Eduard, and Subbiah, Vivek

Published
2022
Full Text
View/download PDF

7. The STELLAR trial:a phase II/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma

Author

Janssen, Jorien B. E., Brahm, Cyrillo G., Driessen, Chantal M. L., Nuver, Janine, Labots, Mariette, Kouwenhoven, Mathilde C. M., Aliaga, Esther Sanchez, Enting, Roelien H., de Groot, Jan Cees, Walenkamp, Annemiek M. E., van Linde, Myra E., Verheul, Henk M. W., Janssen, Jorien B. E., Brahm, Cyrillo G., Driessen, Chantal M. L., Nuver, Janine, Labots, Mariette, Kouwenhoven, Mathilde C. M., Aliaga, Esther Sanchez, Enting, Roelien H., de Groot, Jan Cees, Walenkamp, Annemiek M. E., van Linde, Myra E., and Verheul, Henk M. W.

Abstract

Previously, the tyrosine kinase inhibitor sunitinib failed to show clinical benefit in patients with recurrent glioblastoma. Low intratumoural sunitinib accumulation in glioblastoma patients was reported as a possible explanation for the lack of therapeutic benefit. We designed a randomized phase II/III trial to evaluate whether a high-dose intermittent sunitinib schedule, aimed to increase intratumoural drug concentrations, would result in improved clinical benefit compared to standard treatment with lomustine. Patients with recurrent glioblastoma were randomized 1:1 to high-dose intermittent sunitinib 300 mg once weekly (Q1W, part 1) or 700 mg once every two weeks (Q2W, part 2) or lomustine. The primary end-point was progression-free survival. Based on the pre-planned interim analysis, the trial was terminated for futility after including 26 and 29 patients in parts 1 and 2. Median progression-free survival of sunitinib 300 mg Q1W was 1.5 months (95% CI 1.4–1.7) compared to 1.5 months (95% CI 1.4–1.6) in the lomustine arm (P = 0.59). Median progression-free survival of sunitinib 700 mg Q2W was 1.4 months (95% CI 1.2–1.6) versus 1.6 months (95% CI 1.3–1.8) for lomustine (P = 0.70). Adverse events (≥grade 3) were observed in 25%, 21% and 31% of patients treated with sunitinib 300 mg Q1W, sunitinib 700 mg Q2W and lomustine, respectively (P = 0.92). To conclude, high-dose intermittent sunitinib treatment failed to improve the outcome of patients with recurrent glioblastoma when compared to standard lomustine therapy. Since lomustine remains a poor standard treatment strategy for glioblastoma, innovative treatment strategies are urgently needed.

Published
2024

8. Abstract CT139: The STELLAR trial: A phase II/III study of high-dose intermittent sunitinib in patients with recurrent glioblastoma

Author

Janssen, Jorien B., primary, Brahm, Cyrillo, additional, Driessen, Chantal M., additional, Nuver, Janine, additional, Labots, Mariette, additional, Kouwenhoven, Mathilde C., additional, Aliaga, Esther S., additional, Enting, Roelien H., additional, de Groot, Jan Cees, additional, Berkhof, Johannes, additional, Walenkamp, Annemiek M., additional, Verheul, Henk M., additional, and van Linde, Myra E., additional

Published
2023
Full Text
View/download PDF

9. Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Author

Tesileanu, C. Mircea S., primary, Sanson, Marc, primary, Wick, Wolfgang, primary, Brandes, Alba A., primary, Clement, Paul M., primary, Erridge, Sara C., primary, Vogelbaum, Michael A., primary, Nowak, Anna K., primary, Baurain, Jean-Francois, primary, Mason, Warren P., primary, Wheeler, Helen, primary, Chinot, Olivier L., primary, Gill, Sanjeev, primary, Griffin, Matthew, primary, Rogers, Leland, primary, Taal, Walter, primary, Rudà, Roberta, primary, Weller, Michael, primary, McBain, Catherine, primary, van Linde, Myra E., primary, Aldape, Kenneth, primary, Jenkins, Robert B., primary, Kros, Johan M., primary, Wesseling, Pieter, primary, von Deimling, Andreas, primary, Hoogstrate, Youri, primary, de Heer, Iris, primary, Atmodimedjo, Peggy N., primary, Dubbink, Hendrikus J., primary, Brouwer, Rutger W.W., primary, van IJcken, Wilfred F.J., primary, Cheung, Kin Jip, primary, Golfinopoulos, Vassilis, primary, Baumert, Brigitta G., primary, Gorlia, Thierry, primary, French, Pim J., primary, and van den Bent, Martin J., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Author

van Linde, Myra E., primary, Labots, Mariette, primary, Brahm, Cyrillo G., primary, Hovinga, Koos E., primary, De Witt Hamer, Philip C., primary, Honeywell, Richard J., primary, de Goeij-de Haas, Richard, primary, Henneman, Alex A., primary, Knol, Jaco C., primary, Peters, Godefridus J., primary, Dekker, Henk, primary, Piersma, Sander R., primary, Pham, Thang V., primary, Vandertop, William P., primary, Jiménez, Connie R., primary, and Verheul, Henk M.W., primary

Published
2023
Full Text
View/download PDF

11. Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis

Author

Belgers, Vera, Röttgering, Jantine G, Douw, Linda, Klein, Martin, Ket, Johannes C F, van de Ven, Peter M, Würdinger, Thomas, van Linde, Myra E, Niers, Johanna M, Weber, Markus, Olde Rikkert, Marcel G, Lopez-Sendon, Jose, Arrieta, Oscar, Svendsen, Kristina B, Chagas, Marcos H N, de Almeida, Carlos M O, Kouwenhoven, Mathilde C M, de Witt Hamer, Philip C, Belgers, Vera, Röttgering, Jantine G, Douw, Linda, Klein, Martin, Ket, Johannes C F, van de Ven, Peter M, Würdinger, Thomas, van Linde, Myra E, Niers, Johanna M, Weber, Markus, Olde Rikkert, Marcel G, Lopez-Sendon, Jose, Arrieta, Oscar, Svendsen, Kristina B, Chagas, Marcos H N, de Almeida, Carlos M O, Kouwenhoven, Mathilde C M, and de Witt Hamer, Philip C

Published
2023

12. Efficacy and cost-utility of the eHealth application ‘Oncokompas’, supporting patients with incurable cancer in finding optimal palliative care, tailored to their quality of life and personal preferences: a study protocol of a randomized controlled trial

Author

Schuit, Anouk S., Holtmaat, Karen, Hooghiemstra, Nienke, Jansen, Femke, Lissenberg-Witte, Birgit I., Coupé, Veerle M. H., van Linde, Myra E., Becker-Commissaris, Annemarie, Reijneveld, Jaap C., Zijlstra, Josée M., Sommeijer, Dirkje W., Eerenstein, Simone E. J., and Verdonck-de Leeuw, Irma M.

Published
2019
Full Text
View/download PDF

13. Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis

Author

Belgers, Vera, primary, Röttgering, Jantine G., additional, Douw, Linda, additional, Klein, Martin, additional, Ket, Johannes C.F., additional, van de Ven, Peter M., additional, Würdinger, Thomas, additional, van Linde, Myra E., additional, Niers, Johanna M., additional, Weber, Markus, additional, Olde Rikkert, Marcel G., additional, Lopez-Sendon, Jose, additional, Arrieta, Oscar, additional, Svendsen, Kristina B., additional, Chagas, Marcos H.N., additional, de Almeida, Carlos M.O., additional, Kouwenhoven, Mathilde C.M., additional, and de Witt Hamer, Philip C., additional

Published
2023
Full Text
View/download PDF

16. Cost-Utility of the eHealth Application ‘Oncokompas’, Supporting Incurably Ill Cancer Patients to Self-Manage Their Cancer-Related Symptoms: Results of a Randomized Controlled Trial

Author

Schuit, Anouk S., primary, Holtmaat, Karen, additional, Coupé, Veerle M. H., additional, Eerenstein, Simone E. J., additional, Zijlstra, Josée M., additional, Eeltink, Corien, additional, Becker-Commissaris, Annemarie, additional, van Zuylen, Lia, additional, van Linde, Myra E., additional, Menke-van der Houven van Oordt, C. Willemien, additional, Sommeijer, Dirkje W., additional, Verbeek, Nol, additional, Bosscha, Koop, additional, Nandoe Tewarie, Rishi, additional, Sedee, Robert-Jan, additional, de Bree, Remco, additional, de Graeff, Alexander, additional, de Vos, Filip, additional, Cuijpers, Pim, additional, Verdonck-de Leeuw, Irma M., additional, and Jansen, Femke, additional

Published
2022
Full Text
View/download PDF

17. Efficacy of the eHealth application Oncokompas, facilitating incurably ill cancer patients to self-manage their palliative care needs: A randomized controlled trial

Author

Schuit, Anouk S., primary, Holtmaat, Karen, additional, Lissenberg-Witte, Birgit I., additional, Eerenstein, Simone E.J., additional, Zijlstra, Josée M., additional, Eeltink, Corien, additional, Becker-Commissaris, Annemarie, additional, van Zuylen, Lia, additional, van Linde, Myra E., additional, Menke-van der Houven van Oordt, C. Willemien, additional, Sommeijer, Dirkje W., additional, Verbeek, Nol, additional, Bosscha, Koop, additional, Tewarie, Rishi Nandoe, additional, Sedee, Robert-Jan, additional, de Bree, Remco, additional, de Graeff, Alexander, additional, de Vos, Filip, additional, Cuijpers, Pim, additional, and Verdonck-de Leeuw, Irma M., additional

Published
2022
Full Text
View/download PDF

18. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d'oncologie médicale, Tesileanu, C Mircea S, Sanson, Marc, Wick, Wolfgang, Brandes, Alba A, Clement, Paul M, Erridge, Sara C, Vogelbaum, Michael A, Nowak, Anna K, Baurain, Jean-Francois, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, van Linde, Myra E, Aldape, Kenneth, Jenkins, Robert B, Kros, Johan M, Wesseling, Pieter, von Deimling, Andreas, Hoogstrate, Youri, de Heer, Iris, Atmodimedjo, Peggy N, Dubbink, Hendrikus J, Brouwer, Rutger W W, van IJcken, Wilfred F J, Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G, Gorlia, Thierry, French, Pim J, van den Bent, Martin J, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d'oncologie médicale, Tesileanu, C Mircea S, Sanson, Marc, Wick, Wolfgang, Brandes, Alba A, Clement, Paul M, Erridge, Sara C, Vogelbaum, Michael A, Nowak, Anna K, Baurain, Jean-Francois, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, van Linde, Myra E, Aldape, Kenneth, Jenkins, Robert B, Kros, Johan M, Wesseling, Pieter, von Deimling, Andreas, Hoogstrate, Youri, de Heer, Iris, Atmodimedjo, Peggy N, Dubbink, Hendrikus J, Brouwer, Rutger W W, van IJcken, Wilfred F J, Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G, Gorlia, Thierry, French, Pim J, and van den Bent, Martin J

Abstract

In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82-1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61-1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.

Published
2022

19. Rare central nervous system tumors in adults:a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas, and intracranial germ cell tumors

Author

Ho, Vincent K.Y., Gijtenbeek, Anja J.M.M., Wagemakers, Michiel, Taal, Walter, Van Linde, Myra E., Swaak-Kragten, Annemarie T., Kurt, Erkan, Van Der Weide, Hiske L., Wesseling, Pieter, De Vos, Filip Y., Bromberg, Jacoline E.C., Ho, Vincent K.Y., Gijtenbeek, Anja J.M.M., Wagemakers, Michiel, Taal, Walter, Van Linde, Myra E., Swaak-Kragten, Annemarie T., Kurt, Erkan, Van Der Weide, Hiske L., Wesseling, Pieter, De Vos, Filip Y., and Bromberg, Jacoline E.C.

Abstract

Background: Ependymomas, pilocytic astrocytomas, medulloblastomas, and intracranial germ cell tumors occur relative frequently in children, but are rare central nervous system (CNS) tumors in adults. In this population-based survey, we established incidence, treatment, and survival patterns for these tumors diagnosed in adult patients (≥18 years) over a 30-year period (1989-2018). Methods: Data on 1384 ependymomas, 454 pilocytic astrocytomas, 205 medulloblastomas, and 112 intracranial germ cell tumors were obtained from the Netherlands Cancer Registry (NCR) on the basis of a histopathological diagnosis. For each tumor type, age-standardized incidence rates and estimated annual percentage change were calculated. Trends in incidence and main treatment modalities were reported per 5-year periods. Overall survival was calculated using the Kaplan-Meier method, and relative survival rates were estimated using the Pohar-Perme estimator. Results: Incidence and survival rates remained generally stable for pilocytic astrocytomas, medulloblastomas, and germ cell tumors. Increasing incidence was observed for spinal ependymomas, mostly for myxopapillary ependymomas, and survival improved over time for grade II ependymomas (P <. 01). Treatment patterns varied over time with shifting roles for surgery in ependymomas and for chemotherapy and radiation in medulloblastomas and germinomas. Conclusions: The study provides baseline information for highly needed national and international standard treatment protocols, and thus for further improving patient outcomes in these rare CNS tumors.

Published
2022

20. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype:Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Author

Tesileanu, C. Mircea S., Sanson, Marc, Wick, Wolfgang, Brandes, Alba A., Clement, Paul M., Erridge, Sara C., Vogelbaum, Michael A., Nowak, Anna K., Baurain, Jean Francois, Mason, Warren P., Wheeler, Helen, Chinot, Olivier L., Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, Van Linde, Myra E., Aldape, Kenneth, Jenkins, Robert B., Kros, Johan M., Wesseling, Pieter, Von Deimling, Andreas, Hoogstrate, Youri, De Heer, Iris, Atmodimedjo, Peggy N., Dubbink, Hendrikus J., Brouwer, Rutger W.W., Van IJcken, Wilfred F.J., Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G., Gorlia, Thierry, French, Pim J., Van Den Bent, Martin J., Tesileanu, C. Mircea S., Sanson, Marc, Wick, Wolfgang, Brandes, Alba A., Clement, Paul M., Erridge, Sara C., Vogelbaum, Michael A., Nowak, Anna K., Baurain, Jean Francois, Mason, Warren P., Wheeler, Helen, Chinot, Olivier L., Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, Van Linde, Myra E., Aldape, Kenneth, Jenkins, Robert B., Kros, Johan M., Wesseling, Pieter, Von Deimling, Andreas, Hoogstrate, Youri, De Heer, Iris, Atmodimedjo, Peggy N., Dubbink, Hendrikus J., Brouwer, Rutger W.W., Van IJcken, Wilfred F.J., Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G., Gorlia, Thierry, French, Pim J., and Van Den Bent, Martin J.

Abstract

Purpose: In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase- wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. Patients and Methods: From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Results: Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82-1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61-1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. Conclusions: In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.

Published
2022

21. Study protocol of the GLOW study:maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study

Author

van Opijnen, Mark P., Broekman, Marike L.D., de Vos, Filip Y.F., Cuppen, Edwin, van der Hoeven, Jacobus J.M., van Linde, Myra E., Compter, Annette, Beerepoot, Laurens V., van den Bent, Martin J., Vos, Maaike J., Fiebrich, Helle Brit, Koekkoek, Johan A.F., Hoeben, Ann, Kho, Kuan H., Driessen, Chantal M.L., Jeltema, Hanne Rinck, Robe, Pierre A.J.T., Maas, Sybren L.N., van Opijnen, Mark P., Broekman, Marike L.D., de Vos, Filip Y.F., Cuppen, Edwin, van der Hoeven, Jacobus J.M., van Linde, Myra E., Compter, Annette, Beerepoot, Laurens V., van den Bent, Martin J., Vos, Maaike J., Fiebrich, Helle Brit, Koekkoek, Johan A.F., Hoeben, Ann, Kho, Kuan H., Driessen, Chantal M.L., Jeltema, Hanne Rinck, Robe, Pierre A.J.T., and Maas, Sybren L.N.

Abstract

Background: Glioblastoma (GBM), the most common glial primary brain tumour, is without exception lethal. Every year approximately 600 patients are diagnosed with this heterogeneous disease in The Netherlands. Despite neurosurgery, chemo -and radiation therapy, these tumours inevitably recur. Currently, there is no gold standard at time of recurrence and treatment options are limited. Unfortunately, the results of dedicated trials with new drugs have been very disappointing. The goal of the project is to obtain the evidence for changing standard of care (SOC) procedures to include whole genome sequencing (WGS) and consequently adapt care guidelines for this specific patient group with very poor prognosis by offering optimal and timely benefit from novel therapies, even in the absence of traditional registration trials for this small volume cancer indication. Methods: The GLOW study is a prospective diagnostic cohort study executed through collaboration of the Hartwig Medical Foundation (Hartwig, a non-profit organisation) and twelve Dutch centers that perform neurosurgery and/or treat GBM patients. A total of 200 patients with a first recurrence of a glioblastoma will be included. Dual primary endpoint is the percentage of patients who receive targeted therapy based on the WGS report and overall survival. Secondary endpoints include WGS report success rate and number of targeted treatments available based on WGS reports and number of patients starting a treatment in presence of an actionable variant. At recurrence, study participants will undergo SOC neurosurgical resection. Tumour material will then, together with a blood sample, be sent to Hartwig where it will be analysed by WGS. A diagnostic report with therapy guidance, including potential matching off-label drugs and available clinical trials will then be sent back to the treating physician for discussing of the results in molecular tumour boards and targeted treatment decision making. Discussion: The GLOW s

Published
2022

22. Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics-a prospective multicenter cohort study

Author

MS Medische Oncologie, Cancer, CMM Groep Cuppen, Neurochirurgie, Brain, Pathologie Groep Van Diest, van Opijnen, Mark P, Broekman, Marike L D, de Vos, Filip Y F, Cuppen, Edwin, van der Hoeven, Jacobus J M, van Linde, Myra E, Compter, Annette, Beerepoot, Laurens V, van den Bent, Martin J, Vos, Maaike J, Fiebrich, Helle-Brit, Koekkoek, Johan A F, Hoeben, Ann, Kho, Kuan H, Driessen, Chantal M L, Jeltema, Hanne-Rinck, Robe, Pierre A J T, Maas, Sybren L N, MS Medische Oncologie, Cancer, CMM Groep Cuppen, Neurochirurgie, Brain, Pathologie Groep Van Diest, van Opijnen, Mark P, Broekman, Marike L D, de Vos, Filip Y F, Cuppen, Edwin, van der Hoeven, Jacobus J M, van Linde, Myra E, Compter, Annette, Beerepoot, Laurens V, van den Bent, Martin J, Vos, Maaike J, Fiebrich, Helle-Brit, Koekkoek, Johan A F, Hoeben, Ann, Kho, Kuan H, Driessen, Chantal M L, Jeltema, Hanne-Rinck, Robe, Pierre A J T, and Maas, Sybren L N

Published
2022

23. Cost-Utility of the eHealth Application ‘Oncokompas’, Supporting Incurably Ill Cancer Patients to Self-Manage Their Cancer-Related Symptoms: Results of a Randomized Controlled Trial

Author

MS Hoofd-Hals Chirurgische Oncologie, Cancer, MS Medische Oncologie, Schuit, Anouk S., Holtmaat, Karen, Coupé, Veerle M.H., Eerenstein, Simone E.J., Zijlstra, Josée M., Eeltink, Corien, Becker-Commissaris, Annemarie, van Zuylen, Lia, van Linde, Myra E., Menke-van der Houven van Oordt, C. Willemien, Sommeijer, Dirkje W., Verbeek, Nol, Bosscha, Koop, Nandoe Tewarie, Rishi, Sedee, Robert Jan, de Bree, Remco, de Graeff, Alexander, de Vos, Filip, Cuijpers, Pim, Verdonck-de Leeuw, Irma M., Jansen, Femke, MS Hoofd-Hals Chirurgische Oncologie, Cancer, MS Medische Oncologie, Schuit, Anouk S., Holtmaat, Karen, Coupé, Veerle M.H., Eerenstein, Simone E.J., Zijlstra, Josée M., Eeltink, Corien, Becker-Commissaris, Annemarie, van Zuylen, Lia, van Linde, Myra E., Menke-van der Houven van Oordt, C. Willemien, Sommeijer, Dirkje W., Verbeek, Nol, Bosscha, Koop, Nandoe Tewarie, Rishi, Sedee, Robert Jan, de Bree, Remco, de Graeff, Alexander, de Vos, Filip, Cuijpers, Pim, Verdonck-de Leeuw, Irma M., and Jansen, Femke

Published
2022

24. Rare central nervous system tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas, and intracranial germ cell tumors

Author

Pathologie Pathologen staf, Brain, Cancer, MS Medische Oncologie, Ho, Vincent K Y, Gijtenbeek, Anja J M M, Wagemakers, Michiel, Taal, Walter, van Linde, Myra E, Swaak-Kragten, Annemarie T, Kurt, Erkan, van der Weide, Hiske L, Wesseling, Pieter, de Vos, Filip Y, Bromberg, Jacoline E C, Pathologie Pathologen staf, Brain, Cancer, MS Medische Oncologie, Ho, Vincent K Y, Gijtenbeek, Anja J M M, Wagemakers, Michiel, Taal, Walter, van Linde, Myra E, Swaak-Kragten, Annemarie T, Kurt, Erkan, van der Weide, Hiske L, Wesseling, Pieter, de Vos, Filip Y, and Bromberg, Jacoline E C

Published
2022

25. Efficacy of the eHealth application Oncokompas, facilitating incurably ill cancer patients to self-manage their palliative care needs: A randomized controlled trial

Author

MS Hoofd-Hals Chirurgische Oncologie, Cancer, MS Medische Oncologie, Schuit, Anouk S, Holtmaat, Karen, Lissenberg-Witte, Birgit I, Eerenstein, Simone E J, Zijlstra, Josée M, Eeltink, Corien, Becker-Commissaris, Annemarie, van Zuylen, Lia, van Linde, Myra E, Menke-van der Houven van Oordt, C Willemien, Sommeijer, Dirkje W, Verbeek, Nol, Bosscha, Koop, Tewarie, Rishi Nandoe, Sedee, Robert-Jan, de Bree, Remco, de Graeff, Alexander, de Vos, Filip, Cuijpers, Pim, Verdonck-de Leeuw, Irma M, MS Hoofd-Hals Chirurgische Oncologie, Cancer, MS Medische Oncologie, Schuit, Anouk S, Holtmaat, Karen, Lissenberg-Witte, Birgit I, Eerenstein, Simone E J, Zijlstra, Josée M, Eeltink, Corien, Becker-Commissaris, Annemarie, van Zuylen, Lia, van Linde, Myra E, Menke-van der Houven van Oordt, C Willemien, Sommeijer, Dirkje W, Verbeek, Nol, Bosscha, Koop, Tewarie, Rishi Nandoe, Sedee, Robert-Jan, de Bree, Remco, de Graeff, Alexander, de Vos, Filip, Cuijpers, Pim, and Verdonck-de Leeuw, Irma M

Published
2022

26. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial

Author

MS Medische Oncologie, Cancer, Wen, Patrick Y, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Wick, Antje, de Vos, Filip Y F L, von Bubnoff, Nikolas, van Linde, Myra E, Lai, Albert, Prager, Gerald W, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose A, Kim, Tae Min, Mason, Warren P, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel C, Gazzah, Anas, Pouessel, Damien, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Ilankumaran, Palanichamy, Gasal, Eduard, Subbiah, Vivek, MS Medische Oncologie, Cancer, Wen, Patrick Y, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Wick, Antje, de Vos, Filip Y F L, von Bubnoff, Nikolas, van Linde, Myra E, Lai, Albert, Prager, Gerald W, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose A, Kim, Tae Min, Mason, Warren P, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel C, Gazzah, Anas, Pouessel, Damien, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Ilankumaran, Palanichamy, Gasal, Eduard, and Subbiah, Vivek

Published
2022

27. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Author

Tesileanu, C. Mircea S., primary, Sanson, Marc, additional, Wick, Wolfgang, additional, Brandes, Alba A., additional, Clement, Paul M., additional, Erridge, Sara C., additional, Vogelbaum, Michael A., additional, Nowak, Anna K., additional, Baurain, Jean-Francois, additional, Mason, Warren P., additional, Wheeler, Helen, additional, Chinot, Olivier L., additional, Gill, Sanjeev, additional, Griffin, Matthew, additional, Rogers, Leland, additional, Taal, Walter, additional, Rudà, Roberta, additional, Weller, Michael, additional, McBain, Catherine, additional, van Linde, Myra E., additional, Aldape, Kenneth, additional, Jenkins, Robert B., additional, Kros, Johan M., additional, Wesseling, Pieter, additional, von Deimling, Andreas, additional, Hoogstrate, Youri, additional, de Heer, Iris, additional, Atmodimedjo, Peggy N., additional, Dubbink, Hendrikus J., additional, Brouwer, Rutger W.W., additional, van IJcken, Wilfred F.J., additional, Cheung, Kin Jip, additional, Golfinopoulos, Vassilis, additional, Baumert, Brigitta G., additional, Gorlia, Thierry, additional, French, Pim J., additional, and van den Bent, Martin J., additional

Published
2022
Full Text
View/download PDF

28. Additional file 1 of Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics—a prospective multicenter cohort study

Author

van Opijnen, Mark P., Broekman, Marike L. D., de Vos, Filip Y. F., Cuppen, Edwin, van der Hoeven, Jacobus J. M., van Linde, Myra E., Compter, Annette, Beerepoot, Laurens V., van den Bent, Martin J., Vos, Maaike J., Fiebrich, Helle-Brit, Koekkoek, Johan A. F., Hoeben, Ann, Kho, Kuan H., Driessen, Chantal M. L., Jeltema, Hanne-Rinck, Robe, Pierre A. J. T., and Maas, Sybren L. N.

Abstract

Additional file 1. DNA analysis report.

Published
2022
Full Text
View/download PDF

29. Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

Author

van Linde, Myra E., Labots, Mariette, Brahm, Cyrillo G., Hovinga, Koos E., de Witt Hamer, Philip C., Honeywell, Richard J., de Goeij-de Haas, Richard, Henneman, Alex A., Knol, Jaco C., Peters, Godefridus J., Dekker, Henk, Piersma, Sander R., Pham, Thang V., Vandertop, William P., Jiménez, Connie R., Verheul, Henk M. W., ANS - Systems & Network Neuroscience, ANS - Neurovascular Disorders, Neurosurgery, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Internal medicine, CCA - Treatment and quality of life, Amsterdam Neuroscience - Systems & Network Neuroscience, Clinical pharmacology and pharmacy, Medical oncology laboratory, Amsterdam Neuroscience - Neurovascular Disorders, Amsterdam Neuroscience - Neurodegeneration, and CCA - Cancer Treatment and quality of life

Subjects
Proteomics, Cancer Research, Indoles, Brain Neoplasms, urologic and male genital diseases, female genital diseases and pregnancy complications, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], All institutes and research themes of the Radboud University Medical Center, Oncology, Cell Line, Tumor, Sunitinib, Humans, Pyrroles, Glioblastoma
Abstract

Purpose: Tyrosine kinase inhibitors (TKI) have poor efficacy in patients with glioblastoma (GBM). Here, we studied whether this is predominantly due to restricted blood–brain barrier penetration or more to biological characteristics of GBM. Patients and Methods: Tumor drug concentrations of the TKI sunitinib after 2 weeks of preoperative treatment was determined in 5 patients with GBM and compared with its in vitro inhibitory concentration (IC50) in GBM cell lines. In addition, phosphotyrosine (pTyr)-directed mass spectrometry (MS)-based proteomics was performed to evaluate sunitinib-treated versus control GBM tumors. Results: The median tumor sunitinib concentration of 1.9 μmol/L (range 1.0–3.4) was 10-fold higher than in concurrent plasma, but three times lower than sunitinib IC50s in GBM cell lines (median 5.4 μmol/L, 3.0–8.5; P = 0.01). pTyr-phosphoproteomic profiles of tumor samples from 4 sunitinib-treated versus 7 control patients revealed 108 significantly up- and 23 downregulated (P < 0.05) phosphopeptides for sunitinib treatment, resulting in an EGFR-centered signaling network. Outlier analysis of kinase activities as a potential strategy to identify drug targets in individual tumors identified nine kinases, including MAPK10 and INSR/IGF1R. Conclusions: Achieved tumor sunitinib concentrations in patients with GBM are higher than in plasma, but lower than reported for other tumor types and insufficient to significantly inhibit tumor cell growth in vitro. Therefore, alternative TKI dosing to increase intratumoral sunitinib concentrations might improve clinical benefit for patients with GBM. In parallel, a complex profile of kinase activity in GBM was found, supporting the potential of (phospho)proteomic analysis for the identification of targets for (combination) treatment.

Published
2022

30. Rare central nervous system tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas, and intracranial germ cell tumors

Author

Ho, Vincent K Y, primary, Gijtenbeek, Anja (J) M M, additional, Wagemakers, Michiel, additional, Taal, Walter, additional, van Linde, Myra E, additional, Swaak-Kragten, Annemarie T, additional, Kurt, Erkan, additional, van der Weide, Hiske L, additional, Wesseling, Pieter, additional, de Vos, Filip Y, additional, and Bromberg, Jacoline E C, additional

Published
2022
Full Text
View/download PDF

32. Clinical judgment of the need for professional mental health care in patients with cancer: a qualitative study among oncologists and nurses

Author

Karchoud, Jeanet F., primary, de Kruif, Anja J. Th. C. M., additional, Lamers, Femke, additional, van Linde, Myra E., additional, van Dodewaard-de Jong, Joyce M., additional, Braamse, Annemarie M. J., additional, Sprangers, Mirjam A. G., additional, Beekman, Aartjan T. F., additional, Verheul, Henk M. W., additional, and Dekker, Joost, additional

Published
2021
Full Text
View/download PDF

33. Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)

Author

Subbiah, Vivek, primary, Stein, Alexander, additional, van den Bent, Martin, additional, Wick, Antje, additional, de Vos, Filip Y., additional, von Bubnoff, Nikolas, additional, van Linde, Myra E., additional, Lai, Albert, additional, Prager, Gerald W., additional, Campone, Mario, additional, Fasolo, Angelica, additional, Lopez-Martin, Jose A., additional, Kim, Tae Min, additional, Hofheinz, Ralf-Dieter, additional, Blay, Jean-Yves, additional, Cho, Daniel C., additional, Gazzah, Anas, additional, Pouessel, Damien, additional, Yachnin, Jeffrey, additional, Boran, Aislyn, additional, Burgess, Paul, additional, Ilankumaran, Palanichamy, additional, Gasal, Eduard, additional, and Wen, Patrick Y., additional

Published
2021
Full Text
View/download PDF

34. GOALS2: Glioblastoma broadband power as a longitudinal biomarker for tumor progression

Author

Moraal, Bastiaan, Bruynzeel, Anna, Klein, Martin, Barkhoff, Frederik, Douw, Linda, Würdinger, Thomas, Van Linde, Myra E., Ysbrand Van Der Werf, Hillebrand, Arjan, Zimmermann, Mona, De Witt Hamer, Philip C., Kouwenhoven, Mathilde, and Reijneveld, Jaap

Subjects
treatment planning, Medical Sciences, MEG, Neuroscience and Neurobiology, FOS: Clinical medicine, Neurosciences, glioblastoma, Life Sciences, tumor progression, Cancer-Neuroscience, Neuro-oncology, Medicine and Health Sciences, EEG, prognostic biomarker
Abstract

Glioma is a devastating disease with dismal prognosis, for which individualized treatment through biomarkers is often aimed for, but rarely achieved. This lack of success necessitates a radically different way of thinking, which our group has been exploring in the past years. Recent work shows that glioma growth may not only depend on characteristics of the tumor itself, but is also determined by activity of the healthy tissue around it (Osswald, Solecki Wick & Winkler, 2016; Venkataramani, Tanev, Strahle et al., 2019; Venkatesh, Johung Caretti et al., 2015; Venkatesh, Morishita, Geraghty et al., 2019). Higher activity of neurons surrounding glioma in an animal model has been shown to cause an acceleration of glioma growth through glutamate-dependent “neurogliomal synapses” (Lerhman & Stevens, 2015; Thompson & Sontheimer, 2015; Venkataramani, Tanev, Strahle et al., 2019; Venkatesh, Johung Caretti et al., 2015; Venkatesh, Morishita, Geraghty et al., 2019). Development of these synapses is promoted through increased neuroligin-3 (NLGN3) expression, which is also caused by higher neuronal activity (Venkatesh, Johung Caretti et al., 2015; Venkatesh, Morishita, Geraghty et al., 2019; Venkatesh, Tam & Woo et al., 2017). This causal relationship indicates that higher neuronal activity leads to faster tumor growth. In patients, neuronal activity is difficult to measure directly, but the broadband power and the offset of the signal of electroencephalography (EEG) and magnetoencephalography (MEG) may straightforwardly relate to neuronal activity (Haller, Donoghue & Peterson et al., 2020; Manning, Jacobs, Fried & Kahana; 2009). The offset is defined as part of the aperiodic part of the signal and has been suggested to capture neuronal population spiking activity (Haller, Donoghue & Peterson et al., 2020; Manning et al., 2009). EEG and MEG allow for easy, non-invasive and low-burden measurements of brain activity: a five minute resting recording usually suffices to reliably extract brain activity (Bosma et al., 2009; Bosma et al., 2008; Derks et al., 2019; Douw et al., 2010; Douw et al., 2013; van Dellen, De Witt Hamer, Douw et al., 2013; van Dellen, Douw, Hillebrand et al., 2012). We already translated some of these preclinical results to patients, first showing that lower broadband power (indicating less neuronal activity) at the time of diagnosis relates to lower NLGN3 expression in resected tumor tissue in glioma (Derks et al., 2018). Moreover, lower broadband power relates to longer progression-free survival (PFS), with a hazard ratio (HR) of 2.1, adjusted for known predictors of PFS. In a second study, we replicated these results in the postoperative phase of the disease, showing again that glioma patients with greater broadband power have shorter PFS (HR 2.5, adjusted for known predictors; Belgers et al., 2019). Finally, our most recent work shows that broadband power and offset are particularly increased in the tumor hemisphere and around the tumor itself, even when controlling for regional variance in broadband power and offset using the contralateral hemisphere as a control (Numan et al., 2021). Moreover, we show that these increases in brain activity can be picked up with both MEG and EEG, the latter of which is much more widely available and cheaper in its use. These promising results raise the question whether broadband power and offset of the power spectrum of MEG, EEG or both might be useful as a prognostic biomarker during the disease course of GBM, and particularly during the standard first line treatment period comprised of chemoradiation and adjuvant chemotherapy. In this timeframe, distinguishing between pseudoprogression and actual tumor progression is an important clinical challenge, which limits optimization of treatment (Shah et al., 2013; Brandsma & van den Bent, 2009). Pseudoprogression is the seeming growth of the tumor on traditional imaging during chemoradiation, which is in fact due to radiological changes during and after treatment, such as radionecrosis.

Published
2021
Full Text
View/download PDF

35. Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

Author

Tesileanu, C. Mircea S., Van Den Bent, Martin J., Sanson, Marc, Wick, Wolfgang, Brandes, Alba A., Clement, Paul M., Erridge, Sara C., Vogelbaum, Michael A., Nowak, Anna K., Baurain, Jean F., Mason, Warren P., Wheeler, Helen, Chinot, Olivier L., Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, Van Linde, Myra E., Sabedot, Thais S., Hoogstrate, Youri, Von Deimling, Andreas, De Heer, Iris, Van Ijcken, Wilfred F.J., Brouwer, Rutger W.W., Aldape, Kenneth, Jenkins, Robert B., Dubbink, Hendrikus J., Kros, Johan M., Wesseling, Pieter, Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G., Gorlia, Thierry, Noushmehr, Houtan, French, Pim J., Tesileanu, C. Mircea S., Van Den Bent, Martin J., Sanson, Marc, Wick, Wolfgang, Brandes, Alba A., Clement, Paul M., Erridge, Sara C., Vogelbaum, Michael A., Nowak, Anna K., Baurain, Jean F., Mason, Warren P., Wheeler, Helen, Chinot, Olivier L., Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, Van Linde, Myra E., Sabedot, Thais S., Hoogstrate, Youri, Von Deimling, Andreas, De Heer, Iris, Van Ijcken, Wilfred F.J., Brouwer, Rutger W.W., Aldape, Kenneth, Jenkins, Robert B., Dubbink, Hendrikus J., Kros, Johan M., Wesseling, Pieter, Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G., Gorlia, Thierry, Noushmehr, Houtan, and French, Pim J.

Abstract

Background: Survival in patients with IDH1/2-mutant (mt) anaplastic astrocytomas is highly variable. We have used the prospective phase 3 CATNON trial to identify molecular factors related to outcome in IDH1/2mt anaplastic astrocytoma patients. Methods: The CATNON trial randomized 751 adult patients with newly diagnosed 1p/19q non-codeleted anaplastic glioma to 59.4 Gy radiotherapy +/- concurrent and/or adjuvant temozolomide. The presence of necrosis and/or microvascular proliferation was scored at central pathology review. Infinium MethylationEPIC BeadChip arrays were used for genome-wide DNA methylation analysis and the determination of copy number variations (CNV). Two DNA methylation-based tumor classifiers were used for risk stratification. Next-generation sequencing (NGS) was performed using 1 of the 2 glioma-tailored NGS panels. The primary endpoint was overall survival measured from the date of randomization.Results: Full analysis (genome-wide DNA methylation and NGS) was successfully performed on 654 tumors. Of these, 432 tumors were IDH1/2mt anaplastic astrocytomas. Both epigenetic classifiers identified poor prognosis patients that partially overlapped. A predictive prognostic Cox proportional hazard model identified that independent prognostic factors for IDH1/2mt anaplastic astrocytoma patients included; age, mini-mental state examination score, treatment with concurrent and/or adjuvant temozolomide, the epigenetic classifiers, PDGFRA amplification, CDKN2A/B homozygous deletion, PI3K mutations, and total CNV load. Independent recursive partitioning analysis highlights the importance of these factors for patient prognostication. Conclusion: Both clinical and molecular factors identify IDH1/2mt anaplastic astrocytoma patients with worse outcome. These results will further refine the current WHO criteria for glioma classification.

Published
2021

37. Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

Author

Tesileanu, C Mircea S, primary, van den Bent, Martin J, additional, Sanson, Marc, additional, Wick, Wolfgang, additional, Brandes, Alba A, additional, Clement, Paul M, additional, Erridge, Sara C, additional, Vogelbaum, Michael A, additional, Nowak, Anna K, additional, Baurain, Jean F, additional, Mason, Warren P, additional, Wheeler, Helen, additional, Chinot, Olivier L, additional, Gill, Sanjeev, additional, Griffin, Matthew, additional, Rogers, Leland, additional, Taal, Walter, additional, Rudà, Roberta, additional, Weller, Michael, additional, McBain, Catherine, additional, van Linde, Myra E, additional, Sabedot, Thais S, additional, Hoogstrate, Youri, additional, von Deimling, Andreas, additional, de Heer, Iris, additional, van IJcken, Wilfred F J, additional, Brouwer, Rutger W W, additional, Aldape, Kenneth, additional, Jenkins, Robert B, additional, Dubbink, Hendrikus J, additional, Kros, Johan M, additional, Wesseling, Pieter, additional, Cheung, Kin Jip, additional, Golfinopoulos, Vassilis, additional, Baumert, Brigitta G, additional, Gorlia, Thierry, additional, Noushmehr, Houtan, additional, and French, Pim J, additional

Published
2021
Full Text
View/download PDF

38. Clinical management of emotions in patients with cancer: introducing the approach “emotional support and case finding”

Author

Dekker, Joost, primary, Karchoud, Jeanet, additional, Braamse, Annemarie M J, additional, Buiting, Hilde, additional, Konings, Inge R H M, additional, van Linde, Myra E, additional, Schuurhuizen, Claudia S E W, additional, Sprangers, Mirjam A G, additional, Beekman, Aartjan T F, additional, and Verheul, Henk M W, additional

Published
2020
Full Text
View/download PDF

39. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial

Author

van der Vorst, Maurice J.D.L., primary, Toffoli, Elisa C., additional, Beusink, Marlien, additional, van Linde, Myra E., additional, van Voorthuizen, Theo, additional, Brouwer, Saskia, additional, van Zweeden, Annette A., additional, Vrijaldenhoven, Suzan, additional, Berends, Johan C., additional, Berkhof, Johannes, additional, and Verheul, Henk M.W., additional

Published
2020
Full Text
View/download PDF

42. ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)

Author

Rosenthal, Mark A, primary, Balana, Carmen, additional, van Linde, Myra E, additional, Sayehli, Cyrus, additional, Fiedler, Walter M, additional, Wermke, Martin, additional, Massard, Christophe, additional, Mellinghoff, Ingo K, additional, Khasraw, Mustafa, additional, Ang, Agnes, additional, Rasmussen, Erik, additional, Kast, Johannes, additional, Stienen, Sabine, additional, and Cloughesy, Timothy F, additional

Published
2019
Full Text
View/download PDF

43. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme

Author

Richel Dirk J, van Linde Myra E, Stalpers Lukas JA, Claes An, van Tellingen Olaf, Verhoeff Joost JC, Leenders William PJ, and van Furth Wouter R

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background The relevance of angiogenesis inhibition in the treatment of glioblastoma multiforme (GBM) should be considered in the unique context of malignant brain tumours. Although patients benefit greatly from reduced cerebral oedema and intracranial pressure, this important clinical improvement on its own may not be considered as an anti-tumour effect. Discussion GBM can be roughly separated into an angiogenic component, and an invasive or migratory component. Although this latter component seems inert to anti-angiogenic therapy, it is of major importance for disease progression and survival. We reviewed all relevant literature. Published data support that clinical symptoms are tempered by anti-angiogenic treatment, but that tumour invasion continues. Unfortunately, current imaging modalities are affected by anti-angiogenic treatment too, making it even harder to define tumour margins. To illustrate this we present MRI, biopsy and autopsy specimens from bevacizumab-treated patients. Moreover, while treatment of other tumour types may be improved by combining chemotherapy with anti-angiogenic drugs, inhibiting angiogenesis in GBM may antagonise the efficacy of chemotherapeutic drugs by normalising the blood-brain barrier function. Summary Although angiogenesis inhibition is of considerable value for symptom reduction in GBM patients, lack of proof of a true anti-tumour effect raises concerns about the place of this type of therapy in the treatment of GBM.

Published
2009
Full Text
View/download PDF

44. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with -mutated or -mutated solid tumours

Author

Molenaar, Remco J, Coelen, Robert J S, Khurshed, Mohammed, Roos, Eva, Caan, Matthan W A, van Linde, Myra E, Kouwenhoven, Mathilde, Bramer, Jos A M, Bovée, Judith V M G, Mathôt, Ron A, Klümpen, Heinz-Josef, van Laarhoven, Hanneke W M, van Noorden, Cornelis J F, Vandertop, W Peter, Gelderblom, Hans, van Gulik, Thomas M, Wilmink, Johanna W, Medical oncology, CCA - Cancer Treatment and quality of life, Neurology, and Neurosurgery

Abstract

INTRODUCTION: High-grade chondrosarcoma, high-grade glioma and intrahepatic cholangiocarcinoma are aggressive types of cancer with a dismal outcome. This is due to the lack of effective treatment options, emphasising the need for novel therapies. Mutations in the genes IDH1 and IDH2 (isocitrate dehydrogenase 1 and 2) occur in 60% of chondrosarcoma, 80% of WHO grade II-IV glioma and 20% of intrahepatic cholangiocarcinoma. IDH1/2-mutated cancer cells produce the oncometabolite D-2-hydroxyglutarate (D-2HG) and are metabolically vulnerable to treatment with the oral antidiabetic metformin and the oral antimalarial drug chloroquine.METHODS AND ANALYSIS: We describe a dose-finding phase Ib/II clinical trial, in which patients with IDH1/2-mutated chondrosarcoma, glioma and intrahepatic cholangiocarcinoma are treated with a combination of metformin and chloroquine. Dose escalation is performed according to a 3+3 dose-escalation scheme. The primary objective is to determine the maximum tolerated dose to establish the recommended dose for a phase II clinical trial. Secondary objectives of the study include (1) determination of pharmacokinetics and toxic effects of the study therapy, for which metformin and chloroquine serum levels will be determined over time; (2) investigation of tumour responses to metformin plus chloroquine in IDH1/2-mutated cancers using CT/MRI scans; and (3) whether tumour responses can be measured by non-invasive D-2HG measurements (mass spectrometry and magnetic resonance spectroscopy) of tumour tissue, serum, urine, and/or bile or next-generation sequencing of circulating tumour DNA (liquid biopsies). This study may open a novel treatment avenue for IDH1/2-mutated high-grade chondrosarcoma, glioma and intrahepatic cholangiocarcinoma by repurposing the combination of two inexpensive drugs that are already approved for other indications.ETHICS AND DISSEMINATION: This study has been approved by the medical-ethical review committee of the Academic Medical Center, Amsterdam, The Netherlands. The report will be submitted to a peer-reviewed journal.TRIAL REGISTRATION NUMBER: This article was registered at ClinicalTrials.gov identifier (NCT02496741): Pre-results.

Published
2017

45. Clinical assessment of emotions in patients with cancer: Diagnostic accuracy compared with two reference standards.

Author

Linde, Myra E., Braamse, Annemarie M. J., Collette, Emma H., Hoogendoorn, Adriaan W., Snoek, Frank J., Verheul, Henk M. W., Dekker, Joost, and van Linde, Myra E

Subjects
TUMORS & psychology, ONCOLOGY nursing, RESEARCH, RESEARCH methodology, EVALUATION research, MEDICAL cooperation, COMPARATIVE studies, PSYCHOLOGICAL tests, ALEXITHYMIA, HOSPITAL nursing staff, RESEARCH funding, TUMORS, FAMILY relations, PSYCHOLOGICAL stress
Abstract

Background: Previous research has suggested that clinical assessment of emotions in patients with cancer is suboptimal. However, it is a possibility that well-trained and experienced doctors and nurses do recognize emotions but that they do not evaluate all emotions as necessitating professional mental health care. This implies that the sensitivity of clinical assessment should be tested against the need for professional mental health care as reference standard, instead of emotional distress. We hypothesized that the observed sensitivity of clinical assessment of emotions would be higher when tested against need for professional mental health care as reference standard, compared with emotional distress as reference standard.Patients and Methods: A consecutive series of patients starting with chemotherapy were recruited during their routine clinical care, at a department of medical oncology. Clinical assessment of emotions by medical oncologists and nurses was derived from the patient file. Emotional distress and need for professional mental health care were assessed using the Distress Thermometer and Problem List.Results: Clinical assessment resulted in notes on emotions in 42.2% of the patient files with 36.2% of patients experiencing emotional distress and 10.8% expressing a need for professional mental health care (N = 185). As expected, the sensitivity of clinical assessment of emotions was higher with the reference standard "need for professional mental health care" compared with "emotional distress" (P < .001). For specificity, equivalent results were obtained with the two reference standards (P = .63).Conclusions: Clinical assessment of emotions in patients with cancer may be more accurate than previously concluded. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

49. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours.

Author

Molenaar, Remco J., Coelen, Robert J. S., Khurshed, Mohammed, Roos, Eva, Caan, Matthan W. A., van Linde, Myra E., Kouwenhoven, Mathilde, Bramer, Jos A. M., Bovée, Judith V. M. G., Mathôt, Ron A., Klümpen, Heinz-Josef, van Laarhoven, Hanneke W. M., van Noorden, Cornelis J. F., Vandertop, W. Peter, Gelderblom, Hans, van Gulik, Thomas M., and Wilmink, Johanna W.

Abstract

Introduction High-grade chondrosarcoma, high-grade glioma and intrahepatic cholangiocarcinoma are aggressive types of cancer with a dismal outcome. This is due to the lack of effective treatment options, emphasising the need for novel therapies. Mutations in the genes IDH1 and IDH2 (isocitrate dehydrogenase 1 and 2) occur in 60% of chondrosarcoma, 80% of WHO grade II–IV glioma and 20% of intrahepatic cholangiocarcinoma. IDH1/2-mutated cancer cells produce the oncometabolite D-2-hydroxyglutarate (D-2HG) and are metabolically vulnerable to treatment with the oral antidiabetic metformin and the oral antimalarial drug chloroquine. Methods and analysis We describe a dose-finding phase Ib/II clinical trial, in which patients with IDH1/2-mutated chondrosarcoma, glioma and intrahepatic cholangiocarcinoma are treated with a combination of metformin and chloroquine. Dose escalation is performed according to a 3+3 dose-escalation scheme. The primary objective is to determine the maximum tolerated dose to establish the recommended dose for a phase II clinical trial. Secondary objectives of the study include (1) determination of pharmacokinetics and toxic effects of the study therapy, for which metformin and chloroquine serum levels will be determined over time; (2) investigation of tumour responses to metformin plus chloroquine in IDH1/2-mutated cancers using CT/MRI scans; and (3) whether tumour responses can be measured by non-invasive D-2HG measurements (mass spectrometry and magnetic resonance spectroscopy) of tumour tissue, serum, urine, and/or bile or next-generation sequencing of circulating tumour DNA (liquid biopsies). This study may open a novel treatment avenue for IDH1/2-mutated high-grade chondrosarcoma, glioma and intrahepatic cholangiocarcinoma by repurposing the combination of two inexpensive drugs that are already approved for other indications. Ethics and dissemination This study has been approved by the medical-ethical review committee of the Academic Medical Center, Amsterdam, The Netherlands. The report will be submitted to a peer-reviewed journal. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results